<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ketorolac (ophthalmic): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ketorolac (ophthalmic): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ketorolac (ophthalmic): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9151" href="/d/html/9151.html" rel="external">see "Ketorolac (ophthalmic): Drug information"</a> and <a class="drug drug_patient" data-topicid="12235" href="/d/html/12235.html" rel="external">see "Ketorolac (ophthalmic): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F8346944"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Acular;</li>
<li>Acular LS;</li>
<li>Acuvail</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52869218"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Acular;</li>
<li>Acular LS;</li>
<li>Acuvail</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F10501736"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Anti-inflammatory Agent</span>;</li>
<li>
<span class="list-set-name">Nonsteroidal Anti-inflammatory Drug (NSAID), Ophthalmic</span></li></ul></div>
<div class="block dop drugH1Div" id="F8350500"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3c54556e-771e-43ed-a7ea-8b9581150a82">Postoperative inflammation following cataract extraction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Postoperative inflammation following cataract extraction</b> (<b>0.5% solution):</b> Children ≥2 years and Adolescents: Ophthalmic: Instill 1 drop into affected eye(s) 4 times daily starting 24 hours after cataract surgery and through 14 days after surgery</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="336adb1d-58ca-4e5d-8742-c1739e6b3f69">Postoperative pain, burning, and stinging following corneal refractive surgery</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Postoperative pain, burning, and stinging following corneal refractive surgery (0.4% solution):</b> Children ≥3 years and Adolescents: Ophthalmic: Instill 1 drop into affected eye 4 times daily as needed for up to 4 days after corneal refractive surgery</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3d370684-2ec0-4b63-b0a3-f27e0ece0341">Seasonal allergic conjunctivitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Seasonal allergic conjunctivitis (</b>
<b>0.5% solution):</b> Children ≥2 years and Adolescents: Ophthalmic: Instill 1 drop into affected eye(s) 4 times daily</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51114934"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block dohp drugH1Div" id="F51114935"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doa drugH1Div" id="F8350501"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9151" href="/d/html/9151.html" rel="external">see "Ketorolac (ophthalmic): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="05b80e2e-fa23-4ad9-a900-60684543381f">Cataract surgery, postoperative ocular inflammation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cataract surgery, postoperative ocular inflammation: </b></p>
<p style="text-indent:-2em;margin-left:4em;">0.5% solution (Acular): <b>Ophthalmic:</b> Instill 1 drop into affected eye(s) 4 times daily beginning 24 hours after surgery; continue for 2 weeks.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b88e9566-7e65-44b9-b1c2-29269702d565">Cataract surgery, postoperative ocular pain/inflammation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cataract surgery, postoperative ocular pain/inflammation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">0.45% solution (Acuvail): <b>Ophthalmic:</b> Instill 1 drop into affected eye(s) 2 times daily beginning 24 hours before surgery and continuing on the day of surgery; continue for 2 weeks after surgery.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="511e8ee0-71d3-4de0-ac74-ad4cb02ff770">Corneal refractive surgery, postoperative ocular pain</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Corneal refractive surgery, postoperative ocular pain: </b></p>
<p style="text-indent:-2em;margin-left:2em;">0.4% solution (Acular LS): <b>Ophthalmic:</b> Instill 1 drop into affected eye(s) 4 times daily as needed for up to 4 days after surgery.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3d370684-2ec0-4b63-b0a3-f27e0ece0341">Seasonal allergic conjunctivitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Seasonal allergic conjunctivitis (ocular itching):</b></p>
<p style="text-indent:-2em;margin-left:4em;">0.5% solution (Acular): <b>Ophthalmic:</b> Instill 1 drop into affected eye(s) 4 times daily.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991784"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50988962"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F8346962"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Ophthalmic: Burning sensation of eyes (transient: ≤40%), stinging of eyes (transient: ≤40%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (1% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (1% to 6%), conjunctival hyperemia (1% to 6%), corneal edema, corneal infiltrates (1% to 5%), eye irritation, eye pain (1% to 6%), eyelid edema, increased intraocular pressure (1% to 6%), iritis, lacrimation (1% to 6%), ocular edema (1% to 5%), ocular hyperemia, ophthalmic inflammation, superficial eye infection, superficial keratitis, swelling of eye</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Ophthalmic: Corneal ulcer, dry eye syndrome</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Corneal erosion, corneal perforation, corneal thinning (including corneal melt), epithelial keratopathy (breakdown), keratitis (ulcerative)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm, exacerbation of asthma</p></div>
<div class="block coi drugH1Div" id="F8346954"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Hypersensitivity to ketorolac or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F8346955"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Aspirin/NSAID sensitivity: Use with caution in patients with previous sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other NSAIDs including patients who experience bronchospasm, asthma, rhinitis, or urticaria following NSAID or aspirin therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Corneal effects: May cause keratitis; continued use may cause severe corneal adverse effects, including corneal thinning, erosion, perforation, or ulceration; may result in loss of vision. Discontinue use in patients with evidence of corneal epithelial damage.</p>
<p style="text-indent:-2em;margin-left:4em;">• Delayed healing: Healing time may be slowed or delayed. Use with caution in patients receiving concomitant topical steroid therapy due to an increased risk for healing problems.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bleeding disorders: Use with caution in patients with a predisposition to bleeding (bleeding tendencies or medications which interfere with coagulation). Increased intraocular bleeding (including hyphema) has been reported following surgery.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Use with caution in patients with diabetes mellitus; may be at risk of corneal adverse events, potentially resulting in loss of vision.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular disease: Use with caution in patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, ocular surface disease, or repeat ocular surgeries (within a short timeframe); may be at risk of corneal adverse events, potentially resulting in loss of vision.</p>
<p style="text-indent:-2em;margin-left:4em;">• Rheumatoid arthritis: Use with caution in patients with rheumatoid arthritis; may be at risk of corneal adverse events, potentially resulting in loss of vision.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Postsurgical patients: To minimize the risk of infection following surgery of both eyes, two separate bottles of eye drops (one for each eye) should be used; instruct patients not to use the same bottle for both eyes.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzalkonium chloride: May contain benzalkonium chloride as a preservative.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: The safety and efficacy of Acular LS (0.4% solution) has not been established in postcataract surgery patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Contact lenses: Contact lenses should be removed prior to instillation (contains benzalkonium chloride, which may be adsorbed by contact lens); may be reinserted after 15 minutes (Acular Canadian product monograph).</p>
<p style="text-indent:-2em;margin-left:4em;">• Duration of therapy: Use for more than 1 day prior to surgery or for 14 days beyond surgery may increase risk and severity of corneal adverse events.</p></div>
<div class="block foc drugH1Div" id="F8353219"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Ophthalmic, as tromethamine: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Acular: 0.5% (5 mL) [contains benzalkonium chloride, edetate (edta) disodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Acular LS: 0.4% (5 mL) [contains benzalkonium chloride, edetate (edta) disodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.4% (5 mL); 0.5% (3 mL [DSC], 5 mL, 10 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Ophthalmic, as tromethamine [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Acuvail: 0.45% (10 ea, 30 ea [DSC])</p></div>
<div class="block geq drugH1Div" id="F8346947"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F8353223"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Acular LS Ophthalmic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.4% (per mL): $67.96</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Acular Ophthalmic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5% (per mL): $66.10</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Acuvail Ophthalmic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.45% (per each): $13.37</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Ketorolac Tromethamine Ophthalmic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.4% (per mL): $14.58</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5% (per mL): $21.10 - $21.37</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52869219"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Ophthalmic, as tromethamine: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Acular: 0.5% (5 mL, 10 mL) [contains benzalkonium chloride, edetate (edta) disodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Acular LS: 0.4% (5 mL) [contains benzalkonium chloride, edetate (edta) disodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Acuvail: 0.45% (0.4 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.5% (5 mL, 10 mL)</p></div>
<div class="block admp drugH1Div" id="F52614366"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">For ophthalmic use only. May contain benzalkonium chloride which may be absorbed by contact lenses; contact lenses should not be worn during treatment. Instill drops into affected eye(s); avoid contact of container tip with skin or eyes; wait at least 5 minutes before administering other ophthalmic drops. Apply gentle pressure to lacrimal sac during and immediately following instillation (1 minute) or instruct patient to gently close eyelid after administration, to decrease systemic absorption of ophthalmic drops (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8100087','lexi-content-ref-6704011']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8100087','lexi-content-ref-6704011'])">Ref</a></span>). To minimize the risk of infection following surgery of both eyes, two separate bottles of eye drops (one for each eye) should be used; instruct patients not to use the same bottle for both eyes.</p></div>
<div class="block adm drugH1Div" id="F8353208"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Ophthalmic:</b> For topical ophthalmic use only. Remove contact lenses prior to administration and wait 15 minutes before reinserting. May be used with other eye drops. If using more than 1 ophthalmic product, wait at least 5 minutes between application of each medication. Minimize contamination by not touching the eyelids or surrounding areas with the dropper tip; keep bottle tightly closed when not in use. Also, to minimize the risk of infection following surgery of both eyes, two separate bottles of eye drops (one for each eye) should be used; instruct patients not to use the same bottle for both eyes.</p></div>
<div class="block sts drugH1Div" id="F8349380"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">0.4% and 0.5% solution: Store at 15°C to 25°C (59°F to 77°F). Protect from light.</p>
<p style="text-indent:-2em;margin-left:2em;">0.45% solution: Store at 15°C to 30°C (59°F to 86°F). Store vials in pouch with ends folded; protect from light.</p></div>
<div class="block usep drugH1Div" id="F53570615"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Acular: Treatment of ocular itch associated with seasonal allergic conjunctivitis; postoperative inflammation following cataract extraction (FDA approved in ages ≥2 years and adults)</p>
<p style="text-indent:-2em;margin-left:2em;">Acular LS: Reduction of ocular pain, burning, and stinging after corneal refractive surgery (FDA approved in ages ≥3 years and adults)</p>
<p style="text-indent:-2em;margin-left:2em;">Acuvail: Treatment of postoperative pain and inflammation following cataract surgery (FDA approved in adults)</p></div>
<div class="block mst drugH1Div" id="F8320260"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Acular may be confused with Acthar, Ocular</p>
<p style="text-indent:-2em;margin-left:4em;">Ketorolac may be confused with Ketalar, ketamine, methadone</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299557"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F8349375"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Anticoagulants: Nonsteroidal Anti-Inflammatory Agents (Ophthalmic) may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Ophthalmic): Nonsteroidal Anti-Inflammatory Agents (Ophthalmic) may enhance the adverse/toxic effect of Corticosteroids (Ophthalmic). Healing of ophthalmic tissue during concomitant administration of ophthalmic products may be delayed. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostaglandins (Ophthalmic): Nonsteroidal Anti-Inflammatory Agents (Ophthalmic) may diminish the therapeutic effect of Prostaglandins (Ophthalmic). Nonsteroidal Anti-Inflammatory Agents (Ophthalmic) may enhance the therapeutic effect of Prostaglandins (Ophthalmic). <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F8346950"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Adverse events have been observed in animal reproduction studies. Systemic exposure is decreased with ophthalmic administration (concentrations are ~4% to 8% of the minimum plasma concentration following an oral dose). If ophthalmic agents are needed during pregnancy, the minimum effective dose should be used in combination with punctal occlusion to decrease potential exposure to the fetus (Samples 1988). However, because it may cause prenatal constriction of the ductus arteriosus, the manufacturer recommends that the use of ketorolac ophthalmic drops late in pregnancy be avoided.</p></div>
<div class="block pha drugH1Div" id="F8349383"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits prostaglandin synthesis by decreasing the activity of the enzyme, cyclooxygenase 1 and 2, which results in decreased formation of prostaglandin precursors.</p></div>
<div class="block phk drugH1Div" id="F9772090"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Absorption: Following instillation of ketorolac 0.5% ophthalmic drops 3 times/day, the mean plasma concentrations of ketorolac are ~4% to 8% of the minimum concentration observed following oral doses of 10 mg 4 times/day.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F11390231"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Acular | Acular ls | Acuvail | Torolac</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Acular | Acuvail | Ketopharm | Klenac | Kpan | Poenkerat | Sinalgico</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Acular | Ketorolac medicopharm</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Acular</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Emodol | Etorac | Kelorac | Recular | Todol | Toroaid | Winop | Xidolac</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Aculare</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Ketorolac vision | Medrolgin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Acular | Acular cmc | Acular ls | Cetorolaco de trometamina | Cetorolaco de trometamol | Cetorolaco Trometamol | Cetrolac | Cetrolac md | Clilon | Legrace | Neocular | Optilar | Softalm | Terolac | Teroquatro | Toragesic ofta | Trometamol cetorolaco</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Acular | Ketorolac medano | Ketovision</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Acular | Poenkerat</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Acular | Acular pf</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Acular ls | Acuvail | Expodol k | Kenalgesic | Oftalmotrilac | Ophthaker</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Acular | Ketorolac micro labs | Ketovision</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Acular | Acular ls | Coral | Dustalox | Godekan | Oftalgesic | Rapiblok</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Acular | Acular ls | Dustalox | Poenkerat</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Acular</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Acular | Dolomine | Ketorolac | Ketorolin | Samulgin</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Acular</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Elipa | Torolac</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Acular</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Acular</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Acular | Ketorolac trometamol</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Acular | Errkes</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Acular | Acular pf</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Acular</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Acular | Acular ls | Acuvail | Cadolac | Centagesic | Doloket | K lac | Ked | Ketanov | Ketlur | Ketodrops | Ketolac | Ketostar | Ketromin | Ketsol | Ketzy | Key | Kls | Kt | Ktl | Lokat | Nsaid-K | Oculac | T lac | Torolac</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Acular | Girolac | Ketorolac Abc | Ketorolac Actavis | Ketorolac Doc | Ketorolac EG | Ketorolac Epifarma | Ketorolac Fg | Ketorolac Pensa | Ketorolac rk | Ketorolac Sandoz | Kevindol | Komorebi | Lixidol | Rikedol | Tora Dol</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Acular ls | Acuvail</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Acular | Ketolac | Lopadol</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Acular | Acuvail | Ketlur | Kitolac</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Acular | Acuvail</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Acular | Acular ls | Acuvail</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Acular</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Aculare</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Acular</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Acular</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Acularen | Acularen pf | Bauket | Dustalox | Godek | Kendol | Mardam | Poenkerat | Trub K</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Acular | Acuvail</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Acuvail | Oradol</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Acular</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Acular</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Acular | Acular ls | Dustalox | Godek</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Acular | Acuvail</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Dylac | Ketanov | Ketro | Ketrosan | Oculac | Optiket | Trulac</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Acular</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Acular ls | Acular pf | Acuvail</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Elipa</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Poenkerat</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Acuvail UD</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Ketorolac trometamol rompharm</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Akyular LS | Ketadrop</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Acular ls | Acuvail</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Acular | Acuvail</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Acular</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Acufix | Acular | Enfluat | Medrolgin</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Acular | Ketoro | Sukerin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Acuvail | Medrolgin</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Acular ls | Dolak | Ocudol | Poenkerat</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Acular | Kelopt</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Acular.1">
<a name="Acular.1"></a>Acular (ketorolac tromethamine) [prescribing information]. Irvine, CA: Allergan; June 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Acular.2">
<a name="Acular.2"></a>Acular/Acular LS (ketorolac tromethamine) [product monograph]. St-Laurent, Ontario, Canada: AbbVie Corporation; November 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Acular.3">
<a name="Acular.3"></a>Acular LS (ketorolac tromethamine) [prescribing information]. Madison, NJ: Allergan; March 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Acuvail.1">
<a name="Acuvail.1"></a>Acuvail (ketorolac tromethamine) [prescribing information]. Irvine, CA: Allergan; February 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Acuvail.2">
<a name="Acuvail.2"></a>Acuvail (ketorolac tromethamine) [product monograph]. Markham, Ontario, Canada: Allergan Inc; September 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2903673">
<a name="2903673"></a>Samples JR, Meyer SM. Use of ophthalmic medications in pregnant and nursing women. <i>Am J Ophthalmol</i>. 1988;106(5):616-623.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-ophthalmic-pediatric-drug-information/abstract-text/2903673/pubmed" id="2903673" target="_blank">2903673</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8100087">
<a name="8100087"></a>Urtti A, Salminen L. Minimizing systemic absorption of topically administered ophthalmic drugs. <i>Surv Ophthalmol</i>. 1993;37(6):435-456.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-ophthalmic-pediatric-drug-information/abstract-text/8100087/pubmed" id="8100087" target="_blank">8100087</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6704011">
<a name="6704011"></a>Zimmerman TJ, Kooner KS, Kandarakis AS, Ziegler LP. Improving the therapeutic index of topically applied ocular drugs. <i>Arch Ophthalmol</i>. 1984;102(4):551-553.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ketorolac-ophthalmic-pediatric-drug-information/abstract-text/6704011/pubmed" id="6704011" target="_blank">6704011</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 16006 Version 217.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
